Three-times rejected eye implant finally gets FDA nod for diabetic macular edema
This article was originally published in Clinica
Executive Summary
Illuvien, an intravitreal implant that releases drugs in the back of the eye to treat diabetic macular edema (DME), has finally got the thumbs up from the US FDA, after having been rejected three times already by the agency. Shares of the product’s developers, Alimera and pSivida jumped during after-hours trading on 26 September when they revealed the news and they continued to rally before the markets opened on 29 September. Alimera’s share price rose about 22% in premarket trading on 29 September, while pSivida's stock climbed about 13%.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.